NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026 10:48
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15.95 mln
Float7.03 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
83
/ 100
Strongly outperforming
Debt / Equity
0.10
Very low leverage
ROE
-115
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
IN8bio is a New York-based clinical-stage company working to develop cancer and autoimmune disease treatments using a specialized type of immune cell called gamma-delta T cells. The company has several therapies in active clinical trials, including treatments for brain cancer and blood cancers, with additional programs at earlier stages of research. Founded in 2016 and formerly known as Incysus Therapeutics, IN8bio is working to advance its pipeline from early-stage research through to potential commercialization.
